

Attendance**Members present** [REDACTED]**Guests** [REDACTED]**Presenters:** [REDACTED]**Minute Recorder:** [REDACTED]**Call to Order:** 5:02pm**Approval of Minutes**

Discussion	Action
November minutes	12 Votes - accepted
Old Business: - January Adhoc Vote- all approved New Business: - None	No Discussion

New Products

Drug Name	Decision	Discussion	Vote Count
	All Lines of Business (Where applicable)		
Lynkuet (elinzanetant)	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Voyxact (sibeprenlimab-szsi)	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Lerochol (lerodalcibep-liga)	☐ Must Add ☒ May Add ☐ Do Not Add	[REDACTED] asked if there were any secondary cardiovascular outcomes out yet. [REDACTED] responded not yet at this time.	Must Add- 0 May Add- 12 Do Not Add- 0
Myqorzo (aficamten)	☐ Must Add ☒ May Add ☐ Do Not Add	[REDACTED] asked about the pricing and is the price affected by the strength since there are four different ones? [REDACTED] responded the price listed is for the lowest dose and that it is likely the price is higher with the higher strengths.	Must Add- 0 May Add- 12 Do Not Add- 0
Kygevvi (doxocitine; doxribtimine)	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0

Waskyra (etuvetidigene autotemcel)	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Cardamyst (etripamil)	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
Exdensur (depemokimab-ulaa)	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0

Abbreviated New Products

Drug Name	Decision	Discussion	Vote Count
	All Lines of Business (Where applicable)		

• Armlupeg (pegfilgrastim-unne) • Avtozma (tocilizumab-anoh) • Boncresa (denosumab-mobz) • Contepo (Fosfomycin) IV • Daybue Stix (trofinetide) soln • Filkri (filgrastim-laha) • Itvisma (onasemnogene abeparvovec-brve) IT • Javadin (clonidine) oral soln • Jubereq (denosumab-desu) • Lunsumio VELO (mosunetuzumab-axgb) SQ • Mucinex 12HR Cold & Fever Multi-Symptom (dextromethorphan/guaifenesin/naproxen sodium) ER tablet • Nufymco (ranibizumab-leyk) SQ • Omlyclo (omalizumab-igec) SQ • Orladeyo (berotralstat dihydrochloride) pellets • Osvyrti (denosumab-desu) • Oziltus (denosumab-mobz) • Poherdy (pertuzumab-dpzb) • Rybrevant Faspro (amivantamab/hyaluronidase-lpuj) SQ • Vybrique (sildenafil) oral film • Wegovy (semaglutide) tablets	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 12 Do Not Add- 0
---	---	------	---

New FDA Indications			
Drug Name	Decision	Discussion	Vote Count
	All Lines of Business (Where applicable)		
Accrufer (ferric maltol)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Addyi (flibanserin)	☒ No Change ☐ Change	None	No Change- 12 Change- 0

Akeega (abiraterone/niraparib)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Aqvesme (mitapivat sulfate)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Bluejepa (gepotidacin mesylate)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Breyanzi (lisocabtagene)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Cablivi (caplacizumab-yhdp)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Cerezyme (imuglucerase) injection	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Enhertu (fam-trastuzumab deruxtecan-nxki)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Epkinly (epcoritamab-bysp)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Eylea HD (aflibercept)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Furoscix (furosemide)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Imfinzi (durvalumab)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Jaypirca (pirtobrutinib)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Keytruda (pembrolizumab)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Koselugo (selumetinib)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Linzess (linaclotide)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Mounjaro (tirzepatide)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Omisirge (omidubicel-only)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Padcev (enfortumab vedotin-ejfv)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Recarbrio (imipenem/cilastatin/relebactam)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Rubraca (rucaparib camsylate)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Tecentriq Hybrexa (afezolizumab/hyaluronidase-tqjs)	☒ No Change ☐ Change	None	No Change- 12 Change- 0

Thrombate III (antithrombin III)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Uplinza (inebilizumab-cdon)	☒ No Change ☐ Change	None	No Change- 12 Change- 0
Vraylar (cariprazine HCl)	☒ No Change ☐ Change	None	No Change- 12 Change- 0

DURs

	Discussion
PA Medicaid	None

Formulary Review & Revisions**PA Medicaid**

Drug Name	Recommendation	Decision	Discussion	Vote Count
None	No change	None	None	12

Policies**PA Medicaid**

Policy Name	New/Revision	Decision (vote is for all policies)	Discussion
○ Forzinity (elamipretide) ○ Papzimeos (zopapogene imadenovec-drba)	☒ New Policy ☐ Policy Revision	☒ Approve as Written ☐ Do Not Approve as Written	None
○ Gattex (teduglutide) ○ Phenylketonuria Medications ○ Quantity Limits	☐ New Policy ☒ Policy Revision	☒ Approve as Written ☐ Do Not Approve as Written	None
None	☒ Retire ☐ Do not retire	☒ Approve as Written ☐ Do Not Approve as Written	

PA Medicaid Operational Policies

○ Continuity of Care ○ Coordination of Benefits (COB) ○ Early Refill ○ Medication Adherence Program ○ PBM Provider Pricing Dispute ○ Pharmacy Care Coordination with BH-MCO's ○ Prescription Drug Copayments ○ Specialty Pharmacy Program	☐ New Policy ☒ Policy Revisions	☒ Approve as Written ☐ Do Not Approve as Written	None
---	---	--	------

Final Discussion

None

Next Meeting Date: May 14, 2026**Time Meeting Adjourned:** 5:31pm

Respectfully Submitted:

